Overexpression of YAP1 is Correlated with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 805-811

  Hu, Xiaobin ^a   Xin, Yan ^a   Xiao, Yuping ^a   Zhao, Jing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Metastasis; Prognosis; YAP1

Indexed keywords

EID: 84896421051     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9757-y     Document Type: Article

References (23)

1. Jackson C, Cunningham D, Oliveira J (2009) Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:34–36
2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31:100–110
3. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761
4. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 130:1120–1133
5. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW (2006) Identification and validation of oncogenesin liver cancer using an integrative oncogenomic approach. Cell 125:1253–1267
6. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, AOCS Study group, Bowtell DD, Harvey KF (2011) The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30:2810–2822
7. Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, Zider A (2008) SCALLOPED interacts with YORKIE, the nuclear effector of the Hippo tumor-suppressor pathway in Drosophila. Curr Biol 18:435–441
8. Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J (2008) The TEAD/TEF family of transcription factor Scal-loped mediates Hippo signaling in organ size control. Dev Cell 14:377–387
9. Wu S, Liu Y, Zheng Y, Dong J, Pan D (2008) TheTEAD/TEF family protein Scalloped mediates transcrip-tional output of the Hippo growth-regulatory pathway. Dev Cell 14:388–398
10. Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hipposignaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Dro sophila homolog of YAP. Cell 122:421–434
11. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17:2054–2060
12. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103:12405–12410
13. Tufail R, Jorda M, Zhao W, Reis I, Nawaz Z (2011) Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat 131:743–750
14. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582–1589
15. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA (2009) YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11:1444–1450
16. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115:4576–4585
17. Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA (2006) The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer 37:103–109
18. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, Sung JJ, To KF (2011) Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17:2130–2139
19. Da CL, Xin Y, Zhao J, Luo XD (2009) Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 15:4055–4061
20. Song M, Cheong JH, Kim H, Noh SH, Kim H (2012) Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res 32:3827–3834
21. Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z, Chen WX (2012) Expression of Yes-associated protein in gastric adenocarcinoma and inhibitory effects of its knockdown on gastric cancer cell proliferation and metastasis. Int J Immunopathol Pharmacol 25:583–590
22. Zhang J, Yang YC, Zhu JS, Zhou Z, Chen WX (2012) Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer. Int J Immunopathol Pharmacol 25:977–987
23. Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, Yang K, Tian ZB (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14:5199–5205